These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 22156310)

  • 21. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
    deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
    Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
    Simpson GM; Gratz SS
    Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction between orally administered tyramine and moclobemide.
    Zimmer R; Puech AJ; Philipp F; Korn A
    Acta Psychiatr Scand Suppl; 1990; 360():78-80. PubMed ID: 2248083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
    Korn A; Wagner B; Moritz E; Dingemanse J
    Eur J Clin Pharmacol; 1996; 49(4):273-8. PubMed ID: 8857072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
    Korn A; Eichler HG; Fischbach R; Gasic S
    Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure response to tyramine-enriched meal before and during MAO-inhibition in man: influence of dosage regimen.
    Müller T; Gieschke R; Ziegler WH
    J Neural Transm Suppl; 1988; 26():105-14. PubMed ID: 3162949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of tyramine pressor response effect with oral CX157: A specific reversible MAOI.
    Burch D; Asgharnejad M; Gerson W; Fielding RM; Azzaro AJ
    Clin Pharmacol Drug Dev; 2014 Jan; 3(1):4-12. PubMed ID: 27128224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potentiation of tyramine pressor responses in conscious rats by reversible inhibitors of monoamine oxidase.
    Finberg JP; Youdim MB
    J Neural Transm Suppl; 1988; 26():11-6. PubMed ID: 3162950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations.
    Dingemanse J; Korn A; Pfefen JP; Güntert TW
    Psychopharmacology (Berl); 1992; 106 Suppl():S46-8. PubMed ID: 1347659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
    Dingemanse J; Wood N; Jorga K; Kettler R
    Br J Clin Pharmacol; 1997 Jan; 43(1):41-7. PubMed ID: 9056051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamics of MDL 72974A: absence of effect on the pressor response to oral tyramine.
    Hinze C; Kaschube M; Hardenberg J
    J Neural Transm Suppl; 1994; 41():371-5. PubMed ID: 7931253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
    Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
    Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
    Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-clinical pharmacology of moclobemide. A review of published studies.
    Burkard WP; Da Prada M; Keller HH; Kettler R; Haefely W
    Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.
    Di Stefano AF; Rusca A
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):505-15. PubMed ID: 21850574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB; Weinstock M
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
    Bieck PR; Antonin KH
    J Neural Transm Suppl; 1989; 28():21-31. PubMed ID: 2794993
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.